The DOI matches its Crossref record.
Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart Failure: The Heart Failure ET A Receptor Blockade Trial (HEAT)
Open accessAbstract
Background— The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of selective ET blockade is clinically beneficial is unknown. We investigated hemodynamic and neurohumoral effects of 3 weeks of treatment with various dosages of the orally available ET A antagonist darusentan in addition to modern standard therapy in patients with CHF. Methods and Results— A total of 157 patients with CHF (present or recent NYHA class III of at least 3 months duration), pulmonary capillary wedge pressure ≥12 mm Hg, and a cardiac index ≤2.6 L · min −1 · m −2 were randomly assigned to double-blind treatment with placebo or darusentan (30, 100, or 300 mg/d) in addition to standard therapy. Short-term administration of darusentan increased the cardiac index, but this did not reach statistical significance compared with placebo. The increase in cardiac index was significantly more pronounced after 3 weeks of treatment ( P <0.0001 versus placebo). Pulmonary capillary wedge pressure, pulmonary arterial pressure, pulmonary vascular resistance, and right atrial pressure remained unchanged. Heart rate, mean artery pressure, and plasma catecholamines remained unaltered, but systemic vascular resistance decreased significantly ( P =0.0001). Higher dosages were associated with a trend to more adverse events (including death), particularly early exacerbation of CHF without further benefit on hemodynamics compared with moderate dosages. Conclusions— This study demonstrates for the first time in a large patient population that 3 weeks of selective ET A receptor blockade improves cardiac index in patients with CHF. However, long-term studies are needed to determine whether ET A blockade is beneficial in CHF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Bernardo, B. C., Weeks, K. L., Pretorius, L., & McMullen, J. R. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.005 · Cited by 894
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Pulmonary Hypertension Due to Left Heart Diseases
Vachiéry, J.-L., Adir, Y., Barberà, J. A., Champion, H., Coghlan, J. G., Cottin, V., De Marco, T., Galiè, N., Ghio, S., Gibbs, J. S. R., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.033 · Cited by 636
Pulmonary Hypertension Due to Left Heart Disease
Guazzi, M., & Borlaug, B. A. (2012) · Circulation · doi:10.1161/circulationaha.111.085761 · Cited by 483
Raphael, C., Briscoe, C., Davies, J., Ian Whinnett, Z., Manisty, C., Sutton, R., Mayet, J., & Francis, D. P. (2007) · Heart · doi:10.1136/hrt.2006.089656 · Cited by 477
Metadata
- Authors
- Lüscher, T. F., Enseleit, F., Pacher, R., Mitrovic, V., Schulze, M. R., Willenbrock, R., Dietz, R., Rousson, V., Hürlimann, D., Philipp, S., Notter, T., Noll, G., & Ruschitzka, F.
- Venue
- Circulation
- Published
- 2002-11-19
- Volume
- 106
- Issue
- 21
- Pages
- 2666-2672
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2117259028
- Cited by
- 227
- References
- 0
- FWCI
- 10.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart Failure: The Heart Failure ET A Receptor Blockade Trial (HEAT). https://app.cochat.ai/papers/10.1161/01.cir.0000038497.80095.e1
- The paper
- Lüscher, T. F., Enseleit, F., Pacher, R., Mitrovic, V., Schulze, M. R., Willenbrock, R., Dietz, R., Rousson, V., Hürlimann, D., Philipp, S., Notter, T., Noll, G., & Ruschitzka, F. (2002). Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ET A ) Receptor Blockade in Chronic Heart Failure: The Heart Failure ET A Receptor Blockade Trial (HEAT). Circulation. https://doi.org/10.1161/01.cir.0000038497.80095.e1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.